Clinical Trial Update: Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a [Phase 2]

View source ↗

Summary

Phase 2a trial examining fast-fail strategies in mood and anxiety spectrum disorders evaluating kappa opioid receptor modulation; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• Kappa opioid receptor modulator (investigational)

Snippet

Sponsor: Duke University | Conditions: ANXIETY DISORDERS (or Anxiety and Phobic Neuroses) | Phase 2 | Status: COMPLETED | Results posted: 2019-01-08